Review urges industry input into CA stem cell body to translate basic research
This article was originally published in Clinica
Executive Summary
The Institute of Medicine (IOM) has praised the combined efforts so far from the California Institute of Regenerative Medicine (CIRM) and its governing board – the Independent Citizens' Oversight Committee (ICOC) – but said CIRM should add biotechnology industry expertise to its advisory groups as it seeks to translate scientific discoveries into commercial therapies.